(Q44624734)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14568270%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

title

Clinical outcome and virologic profiles of severe hepatitis B exacerbation due to YMDD mutations (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14568270%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

0 references

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14568270%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

Irene Oi-lin Ng

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14568270%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

Ching-Lung Lai

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14568270%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

1

Man-Fung Yuen

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14568270%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

5

John Chi-Hang Yuen

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14568270%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

10

Sheung-Tat Fan

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14568270%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

author name string

Takanobu Kato

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14568270%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

Masashi Mizokami

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14568270%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

Annie On-On Chan

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14568270%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

He-Jun Yuan

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14568270%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

Danny Ka-Ho Wong

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14568270%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

publication date

1 November 2003

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14568270%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

published in

Journal of Hepatology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14568270%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

volume

39

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14568270%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14568270%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

page(s)

850-855

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14568270%20AND%20SRC:MED&resulttype=core&format=json

Profound suppression of hepatitis B virus replication with lamivudine

20 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900388-X

7 January 2021

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900388-X

7 January 2021

Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900388-X

7 January 2021

Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900388-X

7 January 2021

Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900388-X

7 January 2021

Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in L(-)SddC (3TC) resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900388-X

7 January 2021

Functional analysis of mutations conferring lamivudine resistance on hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900388-X

7 January 2021

YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: A study by in vitro full-length viral DNA transfection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900388-X

7 January 2021

In vivo dynamics and pathogenicity of wild-type and resistant Hepatitis B virus during long-term lamivudine monotherapy - a clinical note

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900388-X

7 January 2021

Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900388-X

7 January 2021

Fatal submassive hepatic necrosis associated with tyrosine-methionine-aspartate-aspartate-motif mutation of hepatitis B virus after long-term lamivudine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900388-X

7 January 2021

Comparison of the efficacy of lamivudine and famciclovir in Asian patients with chronic hepatitis B: results of 24 weeks of therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900388-X

7 January 2021

Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900388-X

7 January 2021

Epidemiologic and virologic characteristics of hepatitis B virus genotype B having the recombination with genotype C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900388-X

7 January 2021

Serological detection of hepatitis B virus genotypes by ELISA with monoclonal antibodies to type-specific epitopes in the preS2-region product

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900388-X

7 January 2021

Hepatitis B therapy: the plot thickens

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900388-X

7 January 2021

Natural history of chronic hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900388-X

7 January 2021

The influence of hepatitis B virus genotype on the development of lamivudine resistance during long-term treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900388-X

7 January 2021

Significance of hepatitis B genotype in acute exacerbation, HBeAg seroconversion, cirrhosis-related complications, and hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900388-X

7 January 2021

Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900388-X

7 January 2021

Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900388-X

7 January 2021

10.1016/S0168-8278(03)00388-X

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14568270%20AND%20SRC:MED&resulttype=core&format=json

release_nvmxkakeevdexhbel5x2jjuz4e

20 December 2019

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/nvmxkakeevdexhbel5x2jjuz4e

24 November 2022

mapped directly with Wikidata item

1 reference